Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 2

Results For "renal"

145 News Found

Chennai gets first structured geriatric continuity-of-care programme
News | March 02, 2026

Chennai gets first structured geriatric continuity-of-care programme

Swayam is designed to support elderly patients and their families with seamless access to coordinated medical care


Emcure partners with Roche to boost nephrology and transplant care in India
News | March 02, 2026

Emcure partners with Roche to boost nephrology and transplant care in India

Emcure to distribute Roche's kidney transplant and anemia drugs in India


Promise Bio launches frontier Epiproteomic Innovation Grant to supercharge biotech R&D
R&D | February 24, 2026

Promise Bio launches frontier Epiproteomic Innovation Grant to supercharge biotech R&D

The program offers selected participants advanced access to Promise Bio’s broad-epiproteomic platform


Novartis’ Vanrafia shows promise in slowing kidney decline in IgA nephropathy
Clinical Trials | February 17, 2026

Novartis’ Vanrafia shows promise in slowing kidney decline in IgA nephropathy

Vanrafia, a potent endothelin A receptor antagonist, received accelerated approval in the US and China in 2025 for reducing proteinuria in adults with IgAN


Fortis Healthcare posts strong Q3 FY26 growth; revenues up 17.5% YoY
News | February 14, 2026

Fortis Healthcare posts strong Q3 FY26 growth; revenues up 17.5% YoY

The company’s consolidated revenues rose 17.5% year-on-year to Rs. 2,265 crore


Biomica seals exclusive global license for groundbreaking microbiome cancer therapy
News | February 09, 2026

Biomica seals exclusive global license for groundbreaking microbiome cancer therapy

The therapy is currently completing Phase 1 clinical trials in renal cell carcinoma and non-small cell lung cancer


Moderna & Merck study: mRNA therapy plus KEYTRUDA cut melanoma recurrence risk by half
R&D | January 21, 2026

Moderna & Merck study: mRNA therapy plus KEYTRUDA cut melanoma recurrence risk by half

The study evaluated patients with stage III/IV melanoma after complete tumor resection


Hansa Biopharma submits FDA application for kidney transplant desensitization treatment
News | December 24, 2025

Hansa Biopharma submits FDA application for kidney transplant desensitization treatment

If approved, imlifidase has the potential to transform the kidney transplant landscape by enabling highly sensitized patients to also have access to a potentially life-changing kidney transplant


Asahi Kasei Pharma to move R&D hub to Shonan iPark in 2027
News | December 24, 2025

Asahi Kasei Pharma to move R&D hub to Shonan iPark in 2027

Shonan iPark was chosen for its globally connected life-science ecosystem, which unites pharmaceutical firms, next-generation medicine developers, AI and digital health innovators, venture capital, and academia